Compare FTEL & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | MIST |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 176.3M |
| IPO Year | 2023 | N/A |
| Metric | FTEL | MIST |
|---|---|---|
| Price | $0.73 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 11.3M | 10.1M |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 27.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,200,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $0.61 | $0.63 |
| 52 Week High | $187.68 | $3.06 |
| Indicator | FTEL | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 42.75 |
| Support Level | $0.62 | $1.90 |
| Resistance Level | $0.75 | $2.22 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 34.27 | 33.20 |
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).